Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Crispr Therapeutics AG (CRSP)
NASDAQ:CRSP
Crispr Therapeutics AG (CRSP) Stock Price & Analysis
5,739 Followers
CRSP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$38.94 - $86.95
Previous Close$55.27
Volume1.17M
Average Volume (3M)1.09M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$1.90B
Total Debt (Recent Filing)$242.16M
Price to Earnings (P/E)-6.3
Beta0.87
Next EarningsFeb 14, 2023
EPS Estimate-$2.29
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price Target$91.38
EPS (TTM)-8.80
Shares Outstanding78,294,139
R-Squared0.22
Standard Deviation0.19
10 Day Avg. Volume926,692
30 Day Avg. Volume1,085,466
Price to Book (P/B)2.04
Price to Sales (P/S)9528.22
Price to Cash Flow (P/CF)13.10
P/FCF Ratio-9.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside65.33% Upside
Rating ConsensusStrong Buy
Alpha0.00900
Number of Analyst Covering10
Crispr Therapeutics AG News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRSP FAQ
What was Crispr Therapeutics AG’s price range in the past 12 months?
Crispr Therapeutics AG lowest stock price was $38.94 and its highest was $86.95 in the past 12 months.
What is Crispr Therapeutics AG’s market cap?
Currently, no data Available
When is Crispr Therapeutics AG’s upcoming earnings report date?
Crispr Therapeutics AG’s upcoming earnings report date is Feb 14, 2023 which is in 8 days.
How were Crispr Therapeutics AG’s earnings last quarter?
Crispr Therapeutics AG released its earnings results on Nov 01, 2022. The company reported -$2.24 earnings per share for the quarter, beating the consensus estimate of -$2.278 by $0.038.
Is Crispr Therapeutics AG overvalued?
According to Wall Street analysts Crispr Therapeutics AG’s price is currently Undervalued.
Does Crispr Therapeutics AG pay dividends?
Crispr Therapeutics AG does not currently pay dividends.
What is Crispr Therapeutics AG’s EPS estimate?
Crispr Therapeutics AG’s EPS estimate is -$2.29.
How many shares outstanding does Crispr Therapeutics AG have?
Crispr Therapeutics AG has 78,294,136 shares outstanding.
What happened to Crispr Therapeutics AG’s price movement after its last earnings report?
Crispr Therapeutics AG reported an EPS of -$2.24 in its last earnings report, beating expectations of -$2.278. Following the earnings report the stock price went up 5.113%.
Which hedge fund is a major shareholder of Crispr Therapeutics AG?
Among the largest hedge funds holding Crispr Therapeutics AG’s share is ARK Investment Management LLC. It holds Crispr Therapeutics AG’s shares valued at 538M.
---
Crispr Therapeutics AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$91.38
$91.38
Blogger Sentiment
Bullish
CRSP Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $105.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Neutral
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.49%
12-Months-Change
Fundamentals
Return on Equity
-30.48%
Trailing 12-Months
Asset Growth
-16.60%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Crispr Therapeutics AG
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.
---
---